Reducing the risk of distant metastases in breast cancer patients: Role of aromatase inhibitors

Cancer Treatment Reviews

Volumn 33, Issue 8, 2007, Pages 681-687

  Mastro, Lucia Del ^a   Clavarezza, Matteo ^a   Venturini, Marco ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

Author keywords

Adjuvant aromatase inhibitor therapy; Breast cancer; Distant metastases

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; METASTASIS; MONOTHERAPY; REVIEW; RISK REDUCTION;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; NEOPLASM METASTASIS;

EID: 36049047008     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.07.014     Document Type: Review

References (39)

1. Hayes D.F., and Kaplan W. Evaluation of patients after primary therapy. In: Harris J.R., Lippman M.E., and Morrow M. (Eds). Disease of the breast (1996), PA: Lippincott-Raven, Philadelphia 629-647
2. Jung J, Hwang G, Lee Y et al. Pamidronate as adjuvant treatment for prevention of bone metastasis in breast cancer. J Clin Oncol 23(16s): 99s [abstr 888].
3. Schmidt-Kittler O., Ragg T., Daskalakis A., et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci 100 (2003) 7737-7742
4. Parker B., and Sukumar S. Distant metastasis in breast cancer: molecular mechanisms and therapeutic targets. Cancer Biol Ther 2 (2003) 14-21
5. Lamerato L., Havstad S., Gandhi S., et al. Breast cancer recurrence and related mortality in US patients with early breast cancer. J Clin Oncol 23 16s (2005) 62s [abstr 738]
6. Elder E.E., Kennedy C.W., Gluch L., et al. Patterns of breast cancer relapse. Eur J Surg Oncol 32 (2006) 922-927
7. Solomayer E.F., Diel I.J., Meyberg G.C., et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59 (2000) 271-278
8. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol 23 (2005) 1636-1643
9. Saphner T., Tormey D.C., and Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14 (1996) 2738-2746
10. Early breast cancer Trialists' Collaborative Group. Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1685-717 [Website appendix to table 4, p. 238-49].
11. Mauriac L, Keshaviah A, Debled M et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007; Feb 14 [Epub ahead of print] doi: 1093/annonc/mdm001.
12. McArthur H.L., Olivotto I., Gelmon K.A., et al. Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. Breast Cancer Res Treat 94 Suppl. 1 (2005) S124 [abstr 3001]
13. Mansell J., Monypenny I.J., Skene A.I., et al. Predictors of early recurrence in postmenopausal women with operable breast cancer. Breast Cancer Res Treat 100 Suppl. 1 (2006) S111 [abstr 2091]
14. Gabos Z., Sinha R., Hanson J., et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24 (2006) 5658-5663
15. Smid M., Wang Y., Klijn J.G.M., et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 24 (2006) 2261-2267
16. Voogd A.C., Nielsen M., Peterse J.L., et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19 (2001) 1688-1697
17. Engel J., Eckel R., Aydemir U., et al. Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 55 (2003) 1186-1195
18. Vicini F.A., Kestin L., Huang R., and Martinez A. Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy?. Cancer 97 (2003) 910-919
19. Le M.G., Arriagada R., Spielmann M., et al. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer 94 (2002) 2813-2820
20. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for post-menopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 (2005) 619-629
21. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
22. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757.
23. Jonat W., Gnant M., Boccardo F., et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 7 (2006) 991-996
24. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
25. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
26. Baum M., Budzar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359 (2002) 2131-2139
27. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
28. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of Italian tamoxifen anastrozole trial. J Clin Oncol 23 (2005) 5138-5147
29. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
30. Jakesz R, Gnant M, Greil R et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5-year analysis of ABCSG trial 8. In: San Antonio Breast Cancer Symposium 2005. (abs 13).
31. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
32. Kennecke H., Olivotto I.A., Speers C., et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 18 (2007) 45-51
33. Jakesz R., Samonigg H., Greil R., et al. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol 23 16s (2005) 10s [abstr 526]
34. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
35. Mamounas E., Jeong J.H., Wickerham L., et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent to treat analysis of NSABP B-33. Breast Cancer Res Treat 100 Suppl. 1 (2006) S22 [abstr 49]
36. Venturini M., and Del Mastro L. Safety of adjuvant aromatase inhibitor therapy. Cancer Treat Rev. 32 (2006) 548-556
37. Dixon J.M., Renshaw L., Young O., et al. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 24 18S (2006) 15s [abstr 552]
38. Geisler J., Haynes B., Anker G., et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20 (2002) 751-757
39. Rose C., Vtoraya O., Plunzaska A., et al. An open randomized trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors anastrozole and letrozole. Eur J Cancer 39 (2003) 2318-2327